CA2005300A1 - Methodes et composes pour la detection precoce et le traitement du diabete insulino-dependant - Google Patents
Methodes et composes pour la detection precoce et le traitement du diabete insulino-dependantInfo
- Publication number
- CA2005300A1 CA2005300A1 CA2005300A CA2005300A CA2005300A1 CA 2005300 A1 CA2005300 A1 CA 2005300A1 CA 2005300 A CA2005300 A CA 2005300A CA 2005300 A CA2005300 A CA 2005300A CA 2005300 A1 CA2005300 A1 CA 2005300A1
- Authority
- CA
- Canada
- Prior art keywords
- idd
- dependent diabetes
- insulin dependent
- early detection
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title abstract 6
- 238000001514 detection method Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 238000011282 treatment Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 title 1
- 239000013060 biological fluid Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Rehabilitation Therapy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28363388A | 1988-12-13 | 1988-12-13 | |
US283,633 | 1988-12-13 | ||
US42705189A | 1989-10-25 | 1989-10-25 | |
US427,051 | 1989-10-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2005300A1 true CA2005300A1 (fr) | 1990-06-13 |
CA2005300C CA2005300C (fr) | 2000-02-15 |
Family
ID=26962160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002005300A Expired - Lifetime CA2005300C (fr) | 1988-12-13 | 1989-12-12 | Methodes et composes pour la detection precoce et le traitement du diabete insulino-dependant |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0448635B1 (fr) |
KR (1) | KR910700459A (fr) |
AU (1) | AU4815890A (fr) |
CA (1) | CA2005300C (fr) |
DE (1) | DE68924354T2 (fr) |
DK (1) | DK112391D0 (fr) |
ES (1) | ES2077670T3 (fr) |
WO (1) | WO1990007117A1 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5762937A (en) * | 1988-12-13 | 1998-06-09 | University Of Florida Research Foundation, Inc. | Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus |
US5645998A (en) * | 1988-12-13 | 1997-07-08 | University Of Florida Research Foundation | Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus |
US6001360A (en) * | 1988-12-13 | 1999-12-14 | University Of Florida | Method and compositions for early detection and treatment of insulin dependent diabetes mellitus |
US5427940A (en) * | 1991-06-03 | 1995-06-27 | Board Of Regents, The University Of Texas System | Engineered cells producing insulin in response to glucose |
EP0543945B1 (fr) * | 1990-08-17 | 1996-10-16 | The University Of Florida | Procedes et compositons de detection precoce et de traitement du diabete sucre insulinodependant |
US5512447A (en) * | 1990-09-07 | 1996-04-30 | The Regents Of The University Of California | Methods for the diagnosis and treatment of diabetes |
WO1992004632A1 (fr) | 1990-09-07 | 1992-03-19 | The Regents Of The University Of California | Procedes de diagnostic et de traitement de diabete |
US6682906B1 (en) * | 1990-09-21 | 2004-01-27 | The Regents Of The University Of California | Cloned glutamic acid decarboxylase |
US5998366A (en) * | 1990-09-21 | 1999-12-07 | The Regents Of The University Of California | Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders |
US5674978A (en) | 1990-09-21 | 1997-10-07 | The Regents Of The University Of California | Peptides derived from glutamic acid decarboxylase |
AU8864791A (en) * | 1990-10-02 | 1992-04-28 | Trigen Incorporated | Antibodies and methods for diagnosis and treatment of diabetes |
US5422339A (en) * | 1991-03-19 | 1995-06-06 | Joslin Diabetes Center, Inc. | Peptides having insulin autoantibody but not insulin receptor binding capacity |
CA2103159A1 (fr) * | 1991-05-15 | 1992-11-16 | Ake Lernmark | Clonage et expression de l'autoantigene de l'acide glutamique decarboxylase des ilots humains |
US5407802A (en) * | 1991-12-26 | 1995-04-18 | Immulogic Pharmaceutical Corporation | Method of accessing the risks of developing type I diabetes |
EP0627934A4 (fr) * | 1992-02-27 | 1997-01-08 | Univ Leland Stanford Junior | Antigene precoce pour diabete autoimmun. |
WO1993021529A1 (fr) * | 1992-04-14 | 1993-10-28 | Duke University | Procede de detection de tumeurs contenant des complexes de p53 et de hsp70 |
US5200318A (en) * | 1992-05-13 | 1993-04-06 | Miles Inc. | Diagnosis of IDDM with a panel of immunoreagents |
DE4237244A1 (de) * | 1992-11-04 | 1994-05-05 | Elias Entwicklungslabor Fuer I | Verfahren zur Herstellung hochreiner humaner GAD-1- und GAD-2- Proteine |
US5561049A (en) * | 1994-09-21 | 1996-10-01 | Behringwerke Ag | Method for detecting antibodies |
US6303325B1 (en) | 1998-05-29 | 2001-10-16 | Dade Behring Inc. | Method for detecting analytes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU633251B2 (en) * | 1988-02-03 | 1993-01-28 | Xoma Corporation | Therapeutic use of anti-t cell immunotoxin for autoimmune diseases |
-
1989
- 1989-12-08 AU AU48158/90A patent/AU4815890A/en not_active Abandoned
- 1989-12-08 ES ES90901345T patent/ES2077670T3/es not_active Expired - Lifetime
- 1989-12-08 DE DE68924354T patent/DE68924354T2/de not_active Revoked
- 1989-12-08 KR KR1019900701752A patent/KR910700459A/ko not_active Application Discontinuation
- 1989-12-08 EP EP90901345A patent/EP0448635B1/fr not_active Revoked
- 1989-12-08 WO PCT/US1989/005570 patent/WO1990007117A1/fr not_active Application Discontinuation
- 1989-12-12 CA CA002005300A patent/CA2005300C/fr not_active Expired - Lifetime
-
1991
- 1991-06-12 DK DK911123A patent/DK112391D0/da not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0448635B1 (fr) | 1995-09-20 |
CA2005300C (fr) | 2000-02-15 |
DK112391A (da) | 1991-06-12 |
ES2077670T3 (es) | 1995-12-01 |
DE68924354D1 (de) | 1995-10-26 |
DE68924354T2 (de) | 1996-02-22 |
DK112391D0 (da) | 1991-06-12 |
EP0448635A1 (fr) | 1991-10-02 |
WO1990007117A1 (fr) | 1990-06-28 |
KR910700459A (ko) | 1991-03-15 |
AU4815890A (en) | 1990-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2005300A1 (fr) | Methodes et composes pour la detection precoce et le traitement du diabete insulino-dependant | |
CA2089742A1 (fr) | Methodes et compositions permettant le depistage precoce et le traitement du diabete sucre insulino-dependant | |
CA2213935A1 (fr) | Agent diagnostique pour le diabete | |
EP0417271A4 (en) | Diagnosis and treatment of insulin dependent diabetes mellitus | |
EP0378924A3 (fr) | Détection de maladies ou dysfonctions neurologiques | |
CA2260769A1 (fr) | Procede immunologique de mise en evidence d'anticorps diriges contre la transglutaminase tissulaire (ttg), utilisation de la ttg a des fins de diagnostic et de controle de therapie et agent pharmaceutique oral contenant de la ttg | |
ES8703023A1 (es) | Un metodo para diagnostico in vitro a fin de detectar la presencia en un paciente de celulas de cancer u otras celulas que produzcan antigenos muninoros. | |
CA2213709A1 (fr) | Nouvelles methodes de diagnostic d'affections benignes de la prostate | |
WO1998016645A3 (fr) | Composes et procedes pour diagnostiquer la tuberculose | |
DE69531345D1 (de) | Rekombinant pgp3, verfahren zu dessen herstellung, und dessen verwendung in der diagnose und therapie | |
CA2104225A1 (fr) | Methode pour le diagnostic et le traitement des maladies associees aux auto-antigenes de l'acide glutamique-decarboxylase | |
SE8701905L (sv) | Foerfarande och kit foer diagnos av iga-nefropati | |
CA2050317A1 (fr) | Methode et trousse pour determiner les activites de phosphorylation et de dephosphorylation | |
CA2334864A1 (fr) | Compose de reference destine a etre utilise dans l'analyse de lots de levosimendan | |
MXPA04003536A (es) | Tratamiento y diagnostico de estados resistentes a insulina. | |
AU6225786A (en) | Receptacle for blood | |
AU4484593A (en) | Method for the determination of lupus anticoagulant antibodies that cause thrombosis | |
SG45161A1 (en) | Methods for the diagnosis of diabetes and prediabetic conditions | |
AU1673892A (en) | Process for diagnosing non-insulin-dependent diabetes mellitus | |
RU1812489C (ru) | Способ диагностики впервые возникшей стенокардии с нестабильным течением | |
SU1622821A1 (ru) | Способ определени активности каталазы в плазме крови | |
SU1296935A1 (ru) | Способ определени индивидуальной чувствительности к гипербарической оксигенации | |
SU1658095A1 (ru) | Способ диагностики атеросклероза сосудов головного мозга | |
Cella | Psychological adjustment and cancer outcome: Levy versus Taylor. | |
RU93030627A (ru) | Метод диагностики ранних стадий сахарного диабета |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |